CJ CheilJedang steps up biotech drive with PHA mass production Korean food and bio company begins mass production of biodegradable plastic
Translated by Ryu Ho-joung 공개 2022-05-16 08:05:48
이 기사는 2022년 05월 13일 08:00 thebell 에 표출된 기사입니다.
South Korea’s CJ CheilJedang started mass production of polyhydroxyalkanoate (PHA) biodegradable plastic at its plant in Pasuruan, Indonesia, the company said on Wednesday, a move in line with its drive to expand its biotech business for future growth.The plant can produce 5,000 metric tons of amorphous PHA a year. PHA is a natural polyester polymer that can be totally decomposed in the ocean and soil and thus is a viable alternative to petroleum-based plastic.
CJ CheilJedang has proprietary amorphous PHA technology, which is used as a modifier to other polymers to improve processing characteristics. It is the only company in the world that succeeded in mass-producing amorphous PHA.
CJ CheilJedang is also building a facility that will produce semi-crystalline PHA, which are used to make things like medical supplies, fibers and straws. The company plans to increase its PHA production capacity to 65,000 metric tons a year by 2025.
“Our ability to produce both amorphous PHA and semi-crystalline PHA gives us an edge over competitors in expanding the business,” an official at CJ CheilJedang said. Other PHA producers like US-based Danimer Scientific and Japan’s Kaneka Corporation make semi-crystalline PHA only.
CJ CheilJedang secured contracts to supply over 5,000 metric tons of amorphous PHA to global companies even before the mass production began.
The global biodegradable plastic market is expected to grow to 16 trillion won ($12.5 billion) in 2025 from about 5 trillion won last year amid tightened environmental rules, especially in developed countries, that are accelerating a shift to environmentally friendly packaging.
Biopharmaceutical ambitions
In July last year, CJ CheilJedang acquired bioinformatics company ChunLab, now renamed CJ Bioscience, for about 100 billion won in a deal to expand its business to include biopharmaceutical products.
CJ Bioscience is still in the red and is expected to take time to turn profitable. CJ CheilJedang recorded 60.9 billion won in goodwill related to CJ Bioscience at the end of 2021, suggesting it believes in the biopharmaceutical company’s growth potential.
CJ CheilJedang also purchased a 76% stake in Batavia Biosciences, a Dutch biotechnology contract manufacturer, for 267.7 billion won in November last year.
“We will continue to make efforts and investment in R&D to strengthen the competitiveness of our biotech business and improve profitability,” the CJ CheilJedang official said. (Reporting by Nu-ri Moon)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '재무개선' AJ네트웍스, 조달비용 '확' 낮췄다
- '9년만에 엑시트' 한앤코, 한온시스템 거래구조 살펴보니
- 한국타이어앤테크놀로지, 한온시스템 인수한다
- [수술대 오른 커넥트웨이브]2대주주 지분매입 나선 MBK, 주식교환 카드 꺼냈다
- [이사회 모니터]이재용 에이비프로바이오 대표, 바이오·반도체 신사업 '드라이브'
- 와이투솔루션, 주인 바뀌어도 '신약' 중심엔 美 합작사 '룩사'
- 아이티센, 부산디지털자산거래소 본격 출범
- 아이에스시, AI·데이터센터 수주 증가에 '날개'
- [이사회 모니터]서정학 IBK증권 대표, ESG위원회도 참여 '영향력 확대'
- SW클라우드 '10주년' 폴라리스오피스, “초격차 밸류업”